Targeted Therapy With Immunoconjugates for Multiple Myeloma

The introduction of proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has markedly increased the survival of multiple myeloma (MM) patients. Also, the unconjugated monoclonal antibodies (mAb) daratumumab (anti-CD38) and elotuzumab (anti-SLAMF7) have revolutionized MM treatment given their...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruins, Wassilis S. C., Zweegman, Sonja, Mutis, Tuna, van de Donk, Niels W. C. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316960/
https://www.ncbi.nlm.nih.gov/pubmed/32636838
http://dx.doi.org/10.3389/fimmu.2020.01155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316960/
https://www.ncbi.nlm.nih.gov/pubmed/32636838
http://dx.doi.org/10.3389/fimmu.2020.01155

Ejemplares similares